Applying a "double-feature" promoter to identify cardiomyocytes differentiated from human embryonic stem cells following transposon-based gene delivery

Tamás I. Orbán, A. Apáti, Andrea Németh, Nóra Varga, Virág Krizsik, Anita Schamberger, Kornélia Szebényi, Zsuzsa Erdei, György Várady, Éva Karászi, L. Homolya, K. Német, Elen Gócza, Csaba Miskey, L. Mátés, Zoltán Ivics, Zsuzsanna Izsvák, B. Sarkadi

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Human embryonic stem (HuES) cells represent a new potential tool for cell-therapy and gene-therapy applications. However, these approaches require the development of efficient, stable gene delivery, and proper progenitor cell and tissue separation methods. In HuES cell lines, we have generated stable, enhanced green fluorescent protein (EGFP)-expressing clones using a transposon-based (Sleeping Beauty) system. This method yielded high percentage of transgene integration and expression. Similarly to a lentiviral expression system, both the undifferentiated state and the differentiation pattern of the HuES cells were preserved. By using the CAG promoter, in contrast to several other constitutive promoter sequences (such as CMV, elongation factor 1α, or phosphoglycerate kinase), an exceptionally high EGFP expression was observed in differentiated cardiomyocytes. This phenomenon was independent of the transgene sequence, methods of gene delivery, copy number, and the integration sites. This "double-feature" promoter behavior, that is providing a selectable marker for transgene expressing undifferentiated stem cells, and also specifically labeling differentiated cardiomyocytes, was assessed by transcriptional profiling. We found a positive correlation between CAG promoter-driven EGFP transcription and expression of cardiomyocyte-specific genes. Our experiments indicate an efficient applicability of transposon-based gene delivery into HuES cells and provide a novel approach to identify differentiated tissues by exploiting a nontypical behavior of a constitutively active promoter, thereby avoiding invasive drug selection methods.

Original languageEnglish
Pages (from-to)1077-1087
Number of pages11
JournalStem Cells
Volume27
Issue number5
DOIs
Publication statusPublished - May 2009

Fingerprint

Cardiac Myocytes
Transgenes
Genes
Stem Cells
Phosphoglycerate Kinase
Peptide Elongation Factor 1
Beauty
Gene Dosage
Cell Separation
Cell- and Tissue-Based Therapy
Genetic Therapy
Clone Cells
Cell Line
Human Embryonic Stem Cells
Pharmaceutical Preparations
enhanced green fluorescent protein

Keywords

  • "Double-feature" promoter
  • CAG promoter
  • Cardiomyocytes
  • Human embryonic stem cells
  • Lentiviral gene delivery
  • Sleeping beauty transposon

ASJC Scopus subject areas

  • Cell Biology
  • Developmental Biology
  • Molecular Medicine

Cite this

Applying a "double-feature" promoter to identify cardiomyocytes differentiated from human embryonic stem cells following transposon-based gene delivery. / Orbán, Tamás I.; Apáti, A.; Németh, Andrea; Varga, Nóra; Krizsik, Virág; Schamberger, Anita; Szebényi, Kornélia; Erdei, Zsuzsa; Várady, György; Karászi, Éva; Homolya, L.; Német, K.; Gócza, Elen; Miskey, Csaba; Mátés, L.; Ivics, Zoltán; Izsvák, Zsuzsanna; Sarkadi, B.

In: Stem Cells, Vol. 27, No. 5, 05.2009, p. 1077-1087.

Research output: Contribution to journalArticle

Orbán, TI, Apáti, A, Németh, A, Varga, N, Krizsik, V, Schamberger, A, Szebényi, K, Erdei, Z, Várady, G, Karászi, É, Homolya, L, Német, K, Gócza, E, Miskey, C, Mátés, L, Ivics, Z, Izsvák, Z & Sarkadi, B 2009, 'Applying a "double-feature" promoter to identify cardiomyocytes differentiated from human embryonic stem cells following transposon-based gene delivery', Stem Cells, vol. 27, no. 5, pp. 1077-1087. https://doi.org/10.1002/stem.45
Orbán, Tamás I. ; Apáti, A. ; Németh, Andrea ; Varga, Nóra ; Krizsik, Virág ; Schamberger, Anita ; Szebényi, Kornélia ; Erdei, Zsuzsa ; Várady, György ; Karászi, Éva ; Homolya, L. ; Német, K. ; Gócza, Elen ; Miskey, Csaba ; Mátés, L. ; Ivics, Zoltán ; Izsvák, Zsuzsanna ; Sarkadi, B. / Applying a "double-feature" promoter to identify cardiomyocytes differentiated from human embryonic stem cells following transposon-based gene delivery. In: Stem Cells. 2009 ; Vol. 27, No. 5. pp. 1077-1087.
@article{de12e975f9f74bc196f43159f9616486,
title = "Applying a {"}double-feature{"} promoter to identify cardiomyocytes differentiated from human embryonic stem cells following transposon-based gene delivery",
abstract = "Human embryonic stem (HuES) cells represent a new potential tool for cell-therapy and gene-therapy applications. However, these approaches require the development of efficient, stable gene delivery, and proper progenitor cell and tissue separation methods. In HuES cell lines, we have generated stable, enhanced green fluorescent protein (EGFP)-expressing clones using a transposon-based (Sleeping Beauty) system. This method yielded high percentage of transgene integration and expression. Similarly to a lentiviral expression system, both the undifferentiated state and the differentiation pattern of the HuES cells were preserved. By using the CAG promoter, in contrast to several other constitutive promoter sequences (such as CMV, elongation factor 1α, or phosphoglycerate kinase), an exceptionally high EGFP expression was observed in differentiated cardiomyocytes. This phenomenon was independent of the transgene sequence, methods of gene delivery, copy number, and the integration sites. This {"}double-feature{"} promoter behavior, that is providing a selectable marker for transgene expressing undifferentiated stem cells, and also specifically labeling differentiated cardiomyocytes, was assessed by transcriptional profiling. We found a positive correlation between CAG promoter-driven EGFP transcription and expression of cardiomyocyte-specific genes. Our experiments indicate an efficient applicability of transposon-based gene delivery into HuES cells and provide a novel approach to identify differentiated tissues by exploiting a nontypical behavior of a constitutively active promoter, thereby avoiding invasive drug selection methods.",
keywords = "{"}Double-feature{"} promoter, CAG promoter, Cardiomyocytes, Human embryonic stem cells, Lentiviral gene delivery, Sleeping beauty transposon",
author = "Orb{\'a}n, {Tam{\'a}s I.} and A. Ap{\'a}ti and Andrea N{\'e}meth and N{\'o}ra Varga and Vir{\'a}g Krizsik and Anita Schamberger and Korn{\'e}lia Szeb{\'e}nyi and Zsuzsa Erdei and Gy{\"o}rgy V{\'a}rady and {\'E}va Kar{\'a}szi and L. Homolya and K. N{\'e}met and Elen G{\'o}cza and Csaba Miskey and L. M{\'a}t{\'e}s and Zolt{\'a}n Ivics and Zsuzsanna Izsv{\'a}k and B. Sarkadi",
year = "2009",
month = "5",
doi = "10.1002/stem.45",
language = "English",
volume = "27",
pages = "1077--1087",
journal = "Stem Cells",
issn = "1066-5099",
publisher = "AlphaMed Press",
number = "5",

}

TY - JOUR

T1 - Applying a "double-feature" promoter to identify cardiomyocytes differentiated from human embryonic stem cells following transposon-based gene delivery

AU - Orbán, Tamás I.

AU - Apáti, A.

AU - Németh, Andrea

AU - Varga, Nóra

AU - Krizsik, Virág

AU - Schamberger, Anita

AU - Szebényi, Kornélia

AU - Erdei, Zsuzsa

AU - Várady, György

AU - Karászi, Éva

AU - Homolya, L.

AU - Német, K.

AU - Gócza, Elen

AU - Miskey, Csaba

AU - Mátés, L.

AU - Ivics, Zoltán

AU - Izsvák, Zsuzsanna

AU - Sarkadi, B.

PY - 2009/5

Y1 - 2009/5

N2 - Human embryonic stem (HuES) cells represent a new potential tool for cell-therapy and gene-therapy applications. However, these approaches require the development of efficient, stable gene delivery, and proper progenitor cell and tissue separation methods. In HuES cell lines, we have generated stable, enhanced green fluorescent protein (EGFP)-expressing clones using a transposon-based (Sleeping Beauty) system. This method yielded high percentage of transgene integration and expression. Similarly to a lentiviral expression system, both the undifferentiated state and the differentiation pattern of the HuES cells were preserved. By using the CAG promoter, in contrast to several other constitutive promoter sequences (such as CMV, elongation factor 1α, or phosphoglycerate kinase), an exceptionally high EGFP expression was observed in differentiated cardiomyocytes. This phenomenon was independent of the transgene sequence, methods of gene delivery, copy number, and the integration sites. This "double-feature" promoter behavior, that is providing a selectable marker for transgene expressing undifferentiated stem cells, and also specifically labeling differentiated cardiomyocytes, was assessed by transcriptional profiling. We found a positive correlation between CAG promoter-driven EGFP transcription and expression of cardiomyocyte-specific genes. Our experiments indicate an efficient applicability of transposon-based gene delivery into HuES cells and provide a novel approach to identify differentiated tissues by exploiting a nontypical behavior of a constitutively active promoter, thereby avoiding invasive drug selection methods.

AB - Human embryonic stem (HuES) cells represent a new potential tool for cell-therapy and gene-therapy applications. However, these approaches require the development of efficient, stable gene delivery, and proper progenitor cell and tissue separation methods. In HuES cell lines, we have generated stable, enhanced green fluorescent protein (EGFP)-expressing clones using a transposon-based (Sleeping Beauty) system. This method yielded high percentage of transgene integration and expression. Similarly to a lentiviral expression system, both the undifferentiated state and the differentiation pattern of the HuES cells were preserved. By using the CAG promoter, in contrast to several other constitutive promoter sequences (such as CMV, elongation factor 1α, or phosphoglycerate kinase), an exceptionally high EGFP expression was observed in differentiated cardiomyocytes. This phenomenon was independent of the transgene sequence, methods of gene delivery, copy number, and the integration sites. This "double-feature" promoter behavior, that is providing a selectable marker for transgene expressing undifferentiated stem cells, and also specifically labeling differentiated cardiomyocytes, was assessed by transcriptional profiling. We found a positive correlation between CAG promoter-driven EGFP transcription and expression of cardiomyocyte-specific genes. Our experiments indicate an efficient applicability of transposon-based gene delivery into HuES cells and provide a novel approach to identify differentiated tissues by exploiting a nontypical behavior of a constitutively active promoter, thereby avoiding invasive drug selection methods.

KW - "Double-feature" promoter

KW - CAG promoter

KW - Cardiomyocytes

KW - Human embryonic stem cells

KW - Lentiviral gene delivery

KW - Sleeping beauty transposon

UR - http://www.scopus.com/inward/record.url?scp=66149170086&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66149170086&partnerID=8YFLogxK

U2 - 10.1002/stem.45

DO - 10.1002/stem.45

M3 - Article

C2 - 19415778

AN - SCOPUS:66149170086

VL - 27

SP - 1077

EP - 1087

JO - Stem Cells

JF - Stem Cells

SN - 1066-5099

IS - 5

ER -